The objective of this audit is to examine the effectiveness of the National Blood Authority’s management of the manufacture and supply of domestic fractionated blood plasma products.

Audit criteria

The ANAO proposes to examine:

  • Was there appropriate planning in place to support strategic procurement for the manufacture and supply of domestic fractionated blood plasma products?
  • Did the procurement process support the achievement of value for money?
  • Were effective contract management and monitoring arrangements established to ensure the delivery of the National Fractionation Agreement for Australia?

Contribute to this audit

We anticipate accepting contributions to this audit until Sunday 29 November 2020.

Files must be less than 20 MB.
Allowed file types: txt pdf doc docx.